SEC Form 4 · accession 0000939767-17-000003
EXELIXIS, INC. · EXEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Lamb
Officer — EVP, Scientific Strategy & CSO
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 8:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000939767
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 3, 2017 | M | 10,000 | $4.42 | A | 83,600 | D | |
| Common Stock | Jan 3, 2017 | M | 60,000 | $5.96 | A | 143,600 | D | |
| Common StockF3 | Jan 3, 2017 | S | 67,600 | $14.63 | D | 76,000 | D | |
| Common StockF4 | Jan 3, 2017 | S | 2,400 | $15.27 | D | 73,600 | D | |
| Common StockF5 | holding | — | — | — | 16,024 | I | By 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F6 | $4.42 | Jan 3, 2017 | M | 10,000 | D | Feb 26, 2010 | Feb 25, 2019 | Common Stock | 10,000 | 0 | D |
| Option (right to buy)F7 | $5.96 | Jan 3, 2017 | M | 60,000 | D | Sep 1, 2010 | Aug 31, 2019 | Common Stock | 60,000 | 15,000 | D |
Explanation of responses
- F1Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- F2The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 27, 2016.
- F3Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.24 to $15.23. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
- F4Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.24 to $15.32. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
- F5Represents 16,024 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of January 3, 2017.
- F6The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 26, 2013.
- F7The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 1, 2013.